Trastuzumab deruxtecan and SG have proved their efficacy over standard chemotherapy in advanced endocrine-resistant HR+, HER2-low breast cancer after second-line therapy, while SG has shown activity even in HER2 non-expressing tumors. The gene discussed is ERBB2; the disease is breast carcinoma.